As illustrated in Figure 4, among the 47 confirmed HBV-HCC patients, the positive rate of ESPL1 (74.5%) was higher than that of PIVKA-II (68.1%) and AFP (6.9%). This evidence concerns the gene ESPL1 and hepatocellular carcinoma.